The Biometry Core provides advanced molecular diagnostics and informatics/biostatistics support to Program Project members. The major molecular diagnostic effort of the Core will be the provision of DNA microarrays containing customized sets of elements as requested by the Project investigators. The arrays will be used for analysis of DNA copy number (array CGH) and gene expression. The Core will consult with Project investigators on the proper design of arrays, collect and maintain the DNA reagents for the arrays, collect and maintain the DNA reagents for the arrays (BACs for DNA copy number, cDNAs and oligonucleotides for gene expression), and prepare for the DNA solutions for printing. The printing will be performed be the UCSF Cancer Center Microarray facility. The Core will then distribute the arrays to requesters, provide instruction on hybridization, fluorescence imaging and analysis, and on data interpretation. The budget for the Core provides the ability to prepare 1,500 DNA samples for printing each year. (Arrays for large scale analysis of gene expression or whole genome scans for DNA copy number variation will be available directly to the Projects from the UCSF Cancer Center Microarray facility.) The Biometry Core will also select probes for specific loci for use in fluorescence in situ hybridization (FISH) analyses or for the custom array measurements described above. The informatics functions of the Core include adaptation of a template UCSF Cancer Center patient tracking and tissue Database (in Oracle) to the specific needs of the Ovarian Program Project, transfer of the legacy data from the existing Filemaker database, development of data models for array CGH, expression arrays, and tissue arrays, and implementation of Web-based user interfaces and links so that investigators at multiple sites have access to patient and tissue information, and the correlated experimental data. The biostatistics functions of the Core include applying statistical, computational and data visualization methods in order to rigorously identify significant correlations between patient outcome, disease phenotype, and DNA copy number variations, and to test hypothesis about the involvement of expression changes in specific genes in tumor progression and response to therapy. These methods will be available to Project investigators over the Web, and will be tightly integrated with the database system.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA064602-06
Application #
6570855
Study Section
Subcommittee G - Education (NCI)
Project Start
2002-03-07
Project End
2003-01-31
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
6
Fiscal Year
2002
Total Cost
$230,600
Indirect Cost
Name
University of California San Francisco
Department
Type
DUNS #
073133571
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Lu, Z; Yang, H; Sutton, M N et al. (2014) ARHI (DIRAS3) induces autophagy in ovarian cancer cells by downregulating the epidermal growth factor receptor, inhibiting PI3K and Ras/MAP signaling and activating the FOXo3a-mediated induction of Rab7. Cell Death Differ 21:1275-89
Cheng, Kwai Wa; Agarwal, Roshan; Mitra, Shreya et al. (2012) Rab25 increases cellular ATP and glycogen stores protecting cancer cells from bioenergetic stress. EMBO Mol Med 4:125-41
Badgwell, D B; Lu, Z; Le, K et al. (2012) The tumor-suppressor gene ARHI (DIRAS3) suppresses ovarian cancer cell migration through inhibition of the Stat3 and FAK/Rho signaling pathways. Oncogene 31:68-79
Zou, Chun-Fang; Jia, Luoqi; Jin, Hongyan et al. (2011) Re-expression of ARHI (DIRAS3) induces autophagy in breast cancer cells and enhances the inhibitory effect of paclitaxel. BMC Cancer 11:22
Cheong, Jae-Ho; Park, Eun Sung; Liang, Jiyong et al. (2011) Dual inhibition of tumor energy pathway by 2-deoxyglucose and metformin is effective against a broad spectrum of preclinical cancer models. Mol Cancer Ther 10:2350-62
Agarwal, Roshan; Carey, Mark; Hennessy, Bryan et al. (2010) PI3K pathway-directed therapeutic strategies in cancer. Curr Opin Investig Drugs 11:615-28
Ishida, Seiko; McCormick, Frank; Smith-McCune, Karen et al. (2010) Enhancing tumor-specific uptake of the anticancer drug cisplatin with a copper chelator. Cancer Cell 17:574-83
Short, John D; Dere, Ruhee; Houston, Kevin D et al. (2010) AMPK-mediated phosphorylation of murine p27 at T197 promotes binding of 14-3-3 proteins and increases p27 stability. Mol Carcinog 49:429-39
Liu, Shuying; Murph, Mandi; Panupinthu, Nattapon et al. (2009) ATX-LPA receptor axis in inflammation and cancer. Cell Cycle 8:3695-701
Huang, Shaoyi; Chang, In Soon; Lin, Wenbo et al. (2009) ARHI (DIRAS3), an imprinted tumour suppressor gene, binds to importins and blocks nuclear import of cargo proteins. Biosci Rep 30:159-68

Showing the most recent 10 out of 117 publications